Q. Bisantrene is not new. How can RAC monetise if it is out of patent?, page-142

Well it gives us 20 plus years patent protection instead of 7 previously
So it's going to add value come buy out time
I'm not happy about waiting longer but it's for a bigger reward It's a much smarter way of demonstrating VALUE and like others have said and we have previously seen with other takeovers the sweet spot with most is Phase 1/2 We won't do a phase 3

How we can almost automatically blend in with extensive chemo use world wide and make it better and safer for patients is a no brainer
Which your brain doesn't seem to be working so well at the moment
No stone thrown at RAC in the last 5 years has ever made a crack to how special our company is and the powers bisantrene has
So stop throwing
stop thinking like a typical IMU holder and look at the way retail shareholders are being treated compared to used and abused
thrown under the bus
Don't end up being the guy that should of could of and us telling you we told you so